TLPH Q3 2025 Earnings Call Summary

Cash Balance: As of September 30, 2025, Talphera reported a cash balance of $21.3 million.
Operating Expenses: Combined R&D and SG&A expenses for 2025 totaled $3.4 million, down from $3.7 million in 2024. Excluding non-cash stock-based compensation, expenses were $3.3 million in 2025 compared to $3.5 million in 2024.
Revised Expense Guidance: The company reduced its expected cash operating expense guidance for 2025 to $14 million to $15 million, down from $16 million to $17 million.

Nephro Study Enrollment: Continued enrollment in the nephro study is progressing, with the restructuring of clinical sites leading to improved enrollment rates. The study size was reduced from 166 to 70 patients to accelerate completion.
Financing: Completed a $17 million financing round, including a $5 million strategic investment from CorMedix, which has a 60-day exclusive negotiation period for potential acquisition post-data release.
New Clinical Sites: Two out of six new target profile sites have been activated, with expectations for the remaining sites to start enrollment soon. The company is optimistic about the potential for these sites to enroll patients rapidly.

Study Completion Timeline: Due to delays in activating new clinical sites, the estimated completion of the nephro study has been pushed to 2026.
PMA Approval: Talphera anticipates submitting for NIAID PMA approval in late 2026.
Enrollment Updates: The company aims to update stakeholders once 35 patients (50% enrollment) are achieved.

Site Activation Delays: The activation of new clinical sites has been slower than anticipated, impacting the overall study timeline.
Regulatory and Institutional Challenges: Some sites, particularly a Veterans Affairs Medical Center, experienced delays due to personnel cuts, adding approximately three to four months to their timeline for enrollment.
Market Conditions: Questions were raised regarding the impact of federal funding volatility on clinical studies, although most sites reported no significant issues.

Enrollment Rates: A question regarding the enrollment speed at new target sites revealed that they are enrolling at a similar rate to existing sites, which has raised concerns about overall enrollment progress.
Impact of Federal Funding: While one site faced delays due to funding cuts, the overall sentiment was that most sites are not currently affected by external funding issues.
Management's Confidence: Despite challenges, management expressed strong confidence in the potential of Nefamostat as a preferred anticoagulant for CRRT, citing positive feedback from investigators.

This summary encapsulates the key points from Talphera's Q3 2025 earnings call, highlighting both progress and challenges faced by the company.

TLPH — Talphera, Inc.